

# Mihai Gheorghiane

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8672586/publications.pdf>

Version: 2024-02-01

166  
papers

17,142  
citations

31976

53  
h-index

14208

128  
g-index

169  
all docs

169  
docs citations

169  
times ranked

15229  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Global Health and Economic Burden of Hospitalizations for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1123-1133.	2.8	1,640
2	Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2217.	7.4	854
3	Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2015, 131, 269-279.	1.6	763
4	Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure<SUBTITLE>The EVEREST Clinical Status Trials</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1332.	7.4	757
5	Chronic Heart Failure in the United States. <i>Circulation</i> , 1998, 97, 282-289.	1.6	721
6	Acute Heart Failure Syndromes. <i>Circulation</i> , 2005, 112, 3958-3968.	1.6	690
7	Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart Failure<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1963.	7.4	603
8	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>European Journal of Heart Failure</i> , 2010, 12, 423-433.	7.1	593
9	Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , 2017, 14, 238-250.	13.7	525
10	Acute Heart Failure Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 53, 557-573.	2.8	515
11	Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. <i>European Heart Journal</i> , 2007, 28, 980-988.	2.2	514
12	Vasopressin V <sub>2</sub> -Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 2690-2696.	1.6	416
13	Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment. <i>American Journal of Medicine</i> , 2006, 119, S3-S10.	1.5	339
14	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	2.2	304
15	Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial. <i>Archives of Internal Medicine</i> , 2007, 167, 1998.	3.8	300
16	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1125.	7.4	297
17	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2251.	7.4	288
18	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017, 38, 1119-1127.	2.2	285

#	ARTICLE	IF	CITATIONS
19	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114.	2.2	274
20	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	4.1	267
21	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 136-145.	4.1	265
22	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , 2015, 12, 220-229.	13.7	238
23	Neurohormonal Inhibition in Heart Failure: Insights from Recent Clinical Trials. <i>American Journal of Cardiology</i> , 2005, 96, 3-9.	1.6	217
24	Digoxin in the Management of Cardiovascular Disorders. <i>Circulation</i> , 2004, 109, 2959-2964.	1.6	206
25	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569.	2.8	193
26	The Burden of Acute Heart Failure on U.S. Emergency Departments. <i>JACC: Heart Failure</i> , 2014, 2, 269-277.	4.1	176
27	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	174
28	Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. <i>Circulation</i> , 2006, 113, 2556-2564.	1.6	164
29	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 995.	6.1	164
30	Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2276-2285.	2.8	145
31	Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy. <i>Circulation Research</i> , 2017, 120, 332-340.	4.5	144
32	Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia. <i>American Journal of Cardiology</i> , 2006, 97, 1064-1067.	1.6	129
33	Therapeutic Targets in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2188-2198.	2.8	124
34	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , 2013, 18, 123-134.	3.9	118
35	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2012, 14, 1056-1066.	7.1	105
36	A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. <i>Heart Failure Reviews</i> , 2012, 17, 485-509.	3.9	100

#	ARTICLE	IF	CITATIONS
37	The Use of Digoxin in Patients With Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1823-1832.	2.8	88
38	Hyperkalemia in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1575-1589.	2.8	86
39	Patient-reported outcomes in the <sc>SOLuble</sc> guanylate Cyclase <sc>stimulator</sc> in <sc>heART failure patientS</sc> with <sc>PRESERVED</sc> ejection fraction (<sc>SOCRATESâ€PRESERVED</sc>) study. <i>European Journal of Heart Failure</i> , 2017, 19, 782-791.	7.1	84
40	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. <i>European Journal of Heart Failure</i> , 2013, 15, 551-559.	7.1	75
41	Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the <sc>COMMANDER HF</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 735-742.	7.1	73
42	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , 2016, 18, 54-65.	7.1	73
43	Medication Dosing in Outpatients With Heart Failure After Implementation of a Practice-Based Performance Improvement Intervention: Findings From IMPROVE HF. <i>Congestive Heart Failure</i> , 2012, 18, 9-17.	2.0	69
44	Population Risk Prediction Models for Incident Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 438-447.	3.9	69
45	Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). <i>European Journal of Heart Failure</i> , 2011, 13, 100-106.	7.1	68
46	Reconsidering the Role for Digoxin in the Management of Acute Heart Failure Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2146.	7.4	61
47	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	7.1	60
48	The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). <i>American Journal of Cardiology</i> , 2005, 96, 18-25.	1.6	59
49	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. <i>JACC: Heart Failure</i> , 2013, 1, 488-496.	4.1	58
50	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 571-579.	2.8	58
51	Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 789.	7.4	58
52	Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the <sc>ASTRONAUT</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 591-600.	7.1	58
53	Medication dosing for heart failure with reduced ejection fraction – opportunities and challenges. <i>European Journal of Heart Failure</i> , 2019, 21, 286-296.	7.1	57
54	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 95-102.	3.9	55

#	ARTICLE	IF	CITATIONS
55	Pharmacology of New Agents for Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 68-73.	1.6	54
56	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq0 0 OrgBT /Over4	1.6	54
57	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1022-1031.	7.1	52
58	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	3.9	51
59	Standards of laboratory practice: cardiac drug monitoring. <i>Clinical Chemistry</i> , 1998, 44, 1096-1109.	3.2	50
60	Targeting the Heart in Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 661-669.	4.1	50
61	Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2017, 4, 402-408.	3.1	50
62	Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2038-2047.	2.8	49
63	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. <i>American Heart Journal</i> , 2009, 157, 957-970.	2.7	48
64	A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1702.	7.4	48
65	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014, 19, 135-152.	3.9	48
66	Management of Comorbid Diabetes Mellitus and Worsening Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2379.	7.4	47
67	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	47
68	Molecular and Cellular Basis of Viable Dysfunctional Myocardium. <i>Circulation: Heart Failure</i> , 2014, 7, 680-691.	3.9	46
69	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	46
70	Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. <i>American Heart Journal</i> , 2003, 145, S51-S54.	2.7	43
71	Hemoconcentration-guided Diuresis in Heart Failure. <i>American Journal of Medicine</i> , 2014, 127, 1154-1159.	1.5	43
72	Improving Postdischarge Outcomes in Patients Hospitalized for Acute Heart Failure Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2456.	7.4	41

#	ARTICLE	IF	CITATIONS
73	Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. <i>American Heart Journal</i> , 2011, 161, 224-232.	2.7	38
74	Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 199.	1.7	38
75	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 440-451.	2.0	38
76	Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. <i>Heart Failure Clinics</i> , 2013, 9, 285-290.	2.1	37
77	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2015, 115, 790-796.	1.6	37
78	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	3.9	34
79	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	2.7	34
80	Contemporary Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 826-831.	3.9	34
81	Lessons learned in acute heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 630-641.	7.1	33
82	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 281-291.	7.1	33
83	Clinical Effectiveness of CRT and ICD Therapy in Heart Failure Patients by Racial/Ethnic Classification. <i>Journal of the American College of Cardiology</i> , 2014, 64, 797-807.	2.8	32
84	Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 218-226.	0.6	30
85	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2013, 15, 679-689.	7.1	30
86	Anticoagulation in heart failure: current status and future direction. <i>Heart Failure Reviews</i> , 2013, 18, 797-813.	3.9	28
87	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1601-1610.	7.1	27
88	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017, 3, 122.	3.0	27
89	Trends in characteristics of cardiovascular clinical trials 2001-2012. <i>American Heart Journal</i> , 2015, 170, 263-272.e2.	2.7	26
90	Introduction to Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 1-4.	1.6	24

#	ARTICLE	IF	CITATIONS
91	Matching Mechanism of Death With Mechanism of Action. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1599-1601.	2.8	24
92	Agents with vasodilator properties in acute heart failure: how to design successful trials. <i>European Journal of Heart Failure</i> , 2015, 17, 652-664.	7.1	24
93	Partial Adenosine A1 Agonist in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 177-203.	1.8	24
94	Moving away from symptoms-based heart failure treatment: misperceptions and real risks for patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 350-352.	7.1	23
95	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1144-1150.	1.6	23
96	Influence of atrial fibrillation on postdischarge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <sc>ASTRONAUT</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 552-562.	7.1	23
97	Mobile health applications in cardiovascular research. <i>International Journal of Cardiology</i> , 2018, 269, 265-271.	1.7	23
98	Trends in Heart Failure Clinical Trials From 2001 to 2012. <i>Journal of Cardiac Failure</i> , 2016, 22, 171-179.	1.7	22
99	Digoxin for the treatment of chronic and acute heart failure syndromes. <i>Acute Cardiac Care</i> , 2009, 11, 83-87.	0.2	21
100	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 677-686.	7.1	21
101	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	2.7	20
102	Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure. <i>Clinical Cardiology</i> , 1998, 21, 261-268.	1.8	19
103	Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	19
104	Surrogate end points in heart failure trials. <i>American Heart Journal</i> , 2003, 145, S67-S70.	2.7	18
105	Redefining the role of biomarkers in heart failure trials: expert consensus document. <i>Heart Failure Reviews</i> , 2017, 22, 263-277.	3.9	18
106	OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization. <i>European Journal of Heart Failure</i> , 2003, 5, 9-12.	7.1	17
107	The Challenge of Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 86-89.	1.6	17
108	Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender. <i>Clinical Research in Cardiology</i> , 2016, 105, 421-431.	3.3	17

#	ARTICLE	IF	CITATIONS
109	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 942-951.	1.6	17
110	Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. <i>European Journal of Heart Failure</i> , 2015, 17, 760-763.	7.1	16
111	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Tj ETQq1 1 0.784314 rgBT /Overl...	1.6	15
112	Same protocol, different continents, different patients: should we continue to conduct global heart failure trials?. <i>European Journal of Heart Failure</i> , 2015, 17, 875-878.	7.1	14
113	Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
114	Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. <i>Discovery Medicine</i> , 2011, 12, 141-51.	0.5	14
115	The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. <i>American Heart Journal</i> , 2009, 158, 437-443.	2.7	13
116	Digoxin use in atrial fibrillation: a critical reappraisal. <i>Lancet, The</i> , 2015, 385, 2330-2332.	13.7	13
117	Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2016, 18, 185-191.	7.1	13
118	Pulmonary Oedema—Therapeutic Targets. <i>Cardiac Failure Review</i> , 2015, 1, 38.	3.0	12
119	Serum chloride in heart failure: a salty prognosis. <i>European Journal of Heart Failure</i> , 2016, 18, 669-671.	7.1	12
120	Is there a clinically meaningful difference in patient reported dyspnea in acute heart failure? An analysis from URGENT Dyspnea. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2017, 46, 300-307.	1.6	12
121	Novel Endpoints for Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 210-216.	3.3	12
122	Acute Dyspnea and Decompensated Heart Failure. <i>Cardiology Clinics</i> , 2018, 36, 63-72.	2.2	12
123	Assessment and management of coronary artery disease in kidney and pancreas transplant candidates. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 51-58.	1.5	12
124	Think Small and Examine the Constituents of Left Ventricular Hypertrophy and Heart Failure: Cardiomyocytes Versus Fibroblasts, Collagen, and Capillaries in the Interstitium. <i>Journal of the American Heart Association</i> , 2015, 4, e002491.	3.7	11
125	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , 2016, 117, 1845-1850.	1.6	11
126	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 768-776.	1.7	11



#	ARTICLE	IF	CITATIONS
127	A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 783-792.	1.7	11
128	In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 580-588.	4.1	10
129	The clinical effects of vasopressin receptor antagonists in heart failure.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, S24-S24.	1.3	10
130	Congestion is an important diagnostic and therapeutic target in heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7 Suppl 1, S12-24.	1.4	10
131	Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. <i>American Heart Journal</i> , 2003, 145, S60-S61.	2.7	9
132	Utility of positron emission tomography for drug development for heart failure. <i>American Heart Journal</i> , 2016, 175, 142-152.	2.7	9
133	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017, 230, 301-303.	1.7	9
134	Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement. <i>European Journal of Heart Failure</i> , 2017, 19, 1424-1426.	7.1	9
135	Evaluative Framework for Phase II Studies in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2013, 1, 123-126.	4.1	8
136	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014, 114, 743-750.	1.6	8
137	Transforming Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	8
138	A new educational program in heart failure drug development. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 411-421.	1.5	8
139	Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?. <i>Journal of Cardiac Failure</i> , 2018, 24, 112-114.	1.7	7
140	One step forward, two steps back. <i>Nature Reviews Cardiology</i> , 2011, 8, 72-73.	13.7	6
141	Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization. <i>European Journal of Heart Failure</i> , 2016, 18, 1190-1192.	7.1	6
142	Digoxin for Worsening Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 365-367.	4.1	6
143	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 597-607.	3.9	6
144	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	1.6	6

#	ARTICLE	IF	CITATIONS
145	Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). <i>American Heart Journal</i> , 2003, 145, S55-S57.	2.7	5
146	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , 2015, 116, 1304-1310.	1.6	5
147	Targeting digoxin dosing to serum concentration: is the bullseye too small?. <i>European Journal of Heart Failure</i> , 2016, 18, 1082-1084.	7.1	5
148	Clinical trials in acute heart failure: beginning of the end or end of the beginning?. <i>European Journal of Heart Failure</i> , 2017, 19, 1358-1360.	7.1	5
149	A roadmap to inpatient heart failure management. <i>Journal of Cardiology</i> , 2015, 65, 26-31.	1.9	4
150	Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. <i>International Journal of Cardiology</i> , 2017, 248, 414-420.	1.7	4
151	Past, present, and future of acute heart failure clinical trials—a high-risk population in search of a strategy. <i>European Journal of Heart Failure</i> , 2018, 20, 839-841.	7.1	4
152	Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 761-768.	2.6	3
153	Revisiting Cardiac Injury During Acute Heart Failure: Further Characterization and a Possible Target for Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 141-146.	1.6	3
154	Clinical profiles in acute heart failure: one size fits all or not at all?. <i>European Journal of Heart Failure</i> , 2017, 19, 1255-1257.	7.1	3
155	Introduction. <i>American Journal of Cardiology</i> , 2008, 101, S1-S2.	1.6	2
156	Performance Matters in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 131-132.	2.8	2
157	Contemporary Cardiovascular Device Clinical Trials (Trends and Patterns 2001 to 2012). <i>American Journal of Cardiology</i> , 2015, 116, 307-312.	1.6	2
158	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , 2016, 214, 16-18.	1.7	2
159	Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 870-872.	7.1	2
160	Protein turnover in the failing heart: an ever-changing landscape. <i>European Journal of Heart Failure</i> , 2017, 19, 1218-1221.	7.1	2
161	Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2004, 5, 160-2.	0.1	2
162	Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. <i>Heart Failure Reviews</i> , 2021, 26, 1529-1529.	3.9	1

#	ARTICLE	IF	CITATIONS
163	Closing statement. American Journal of Medicine, 2004, 116, 89-90.	1.5	0
164	Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article "The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy" Cardiovascular Drugs and Therapy, 2009, 23, 335-336.	2.6	0
165	Hospitalizations for Heart Failure. Heart Failure Clinics, 2013, 9, xi-xii.	2.1	0
166	Letter by Abu Daya et al Regarding Article, "Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction, Contributions of Collagen and Titin" Circulation, 2015, 132, e248.	1.6	0